J.P. Bercu
Advertisement
J.P. Bercu is senior director in nonclinical safety and pathobiology, Gilead Sciences.
Articles by J.P. Bercu
Advertisement
Latest Updated Articles
Managing the Risk of Nitrosamine ImpuritiesMarch 15th 2021
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
What Novartis's $3.2 Billion Enzyme Licensing Deal Means for Formulation
2
AAPS PharmSci 360: CMC Strategies, Part 1
3
CPHI Milan Names 2026 Pharma Awards Finalists
4
AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 1
5